Instil Bio, Inc. (TIL)

NASDAQ: TIL · IEX Real-Time Price · USD
5.70
-0.66 (-10.38%)
Aug 19, 2022 4:00 PM EDT - Market closed
-10.38%
Market Cap 739.26M
Revenue (ttm) n/a
Net Income (ttm) -211.46M
Shares Out 129.69M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 300,531
Open 6.15
Previous Close 6.36
Day's Range 5.60 - 6.21
52-Week Range 3.90 - 23.68
Beta n/a
Analysts Buy
Price Target 24.74 (+334.0%)
Earnings Date Aug 10, 2022

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, ... [Read more...]

Industry Biotechnology
IPO Date Mar 19, 2021
Employees 463
Stock Exchange NASDAQ
Ticker Symbol TIL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TIL stock is "Buy." The 12-month stock price forecast is 24.74, which is an increase of 334.04% from the latest price.

Price Target
$24.74
(334.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site

Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor M...

DALLAS, May 27, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for ...

Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)

Presentation to highlight correlates of response to TIL product attributes and elements of Instil Bio's cell therapy data analytics and computational platform Presentation to highlight correlates of res...

Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

DALLAS, May 16, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TI...

Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent

Instil Bio to Present at the Cowen 42nd Annual Health Care Conference

DALLAS, March 02, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies fo...

Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...

Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies f...

Instil Bio to Present at Upcoming Investor Conferences in November

DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...

Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma

Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma

Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response

Instil Bio to Present at the Jefferies Virtual Healthcare Conference

DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...

Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

IPO in March 2021 raising $368M in gross proceeds

At a Recent Cancer Research Conference, Instil Bio Stole the Show

The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.

Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma

DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma...

Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association...

67% overall response rate and 19% complete response rate in 21 patients

Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additio...

DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...

The IPO Market Had A Busy Week

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

Three Biotechs and a Marijuana Lender Begin Trading. Here's How They Did.

Connect Biopharma, Finch Therapeutics, Instil Bio, and AFC Gamma made their public-equity market debuts Friday.

Other symbols: AFCGCNTBFNCH

Instil Bio Announces Pricing of Upsized Initial Public Offering

DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...